Get started
PROFARMA ON NMPP

PROFARMA ON NM

6.66BRLD
+0.15+2.30%
At close at Feb 28, 21:00 GMT
BRL
No trades
See on Supercharts
Overview
Financials
Discussions Technicals Seasonals

PFRM3F fundamentals

Key facts

Market capitalization‪827.62 M‬BRL
Dividend yield (indicated)0.00%
Price to earnings Ratio (TTM)7.43
Basic EPS (TTM)0.88BRL
Founded1961
Employees (FY)—
CEOSammy Birmarcker
Websiteprofarma.com.br
About

Profarma Distribuidora de Produtos Farmaceuticos SA provides wholesale operations to pharmaceutical retailers, with the sale of medicines and health and beauty products. It operates through the following segments: Pharmaceutical Distribution, Hospital and Specialties, and Retail. The Pharmaceutical Distribution segment is the core business and comprises wholesale operations to pharmaceutical retail, with the sale of medicines and personal care and beauty products. The Hospital and Specialties segment in hospital and dermatological products and vaccines. The Retail segment deals with pharmaceutical retail through the chains Drogasmil and Tamoio. The company was founded by Manoel Birmarcker in May 1961 and is headquartered in Rio de Janeiro, Brazil.

Ownership
‪‪122.61 M‬‬
Closely held shares
‪‪82.16 M‬‬ (67%)
Free Float shares
‪‪40.46 M‬‬ (33%)
Closely held shares
‪‪82.16 M‬‬ (67%)
Free Float shares
‪‪40.46 M‬‬ (33%)
Capital structure
Market cap
‪‪827.62 M‬‬
Debt
‪‪1.17 B‬‬
Minority interest
‪‪281.65 M‬‬
Cash & equivalents
‪‪231.28 M‬‬
Enterprise value
‪‪2.05 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪827.62 M‬‬
Price to earning ratio (P/E)
7.43x
Price to sales ratio (P/S)
0.09x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
7.43x
Price to sales ratio (P/S)
0.09x
Valuation ratios
‪0.00‬
‪0.03‬
‪0.05‬
‪0.08‬
‪0.10‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪3.00‬
‪6.00‬
‪9.00‬
‪12.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪0.05%‬
‪0.55%‬
‪1.05%‬
‪1.55%‬
‪2.05%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪700.00 M‬‬
‪‪1.40 B‬‬
‪‪2.10 B‬‬
‪‪2.80 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪700.00 M‬‬
‪‪1.40 B‬‬
‪‪2.10 B‬‬
‪‪2.80 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪700.00 M‬‬
‪‪1.40 B‬‬
‪‪2.10 B‬‬
‪‪2.80 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Pharmaceutical Distribution
Pharmaceutical Retail
By country
Period: 2023
Brazil

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '20
Q3 '20
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
‪‪1.05 B‬‬
‪‪1.40 B‬‬
Actual
Earnings
Next:Mar 12, 2025
Q2 '20
Q3 '20
‪−0.02‬
‪−0.02‬
‪−0.01‬
‪−0.01‬
‪0.00‬
Actual

Dividends

Dividend yield, history and sustainability

Dividend summary
55.77%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
7.24%
Last payment
0.243
Last ex-date
Jan 2, 2025
Dividend history
‪0.0%‬
‪1.5%‬
‪3.0%‬
‪4.5%‬
‪6.0%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.09‬
‪0.18‬
‪0.27‬
‪0.36‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−500.00 M‬‬
‪0.00‬
‪‪500.00 M‬‬
‪‪1.00 B‬‬
‪‪1.50 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪1.00 B‬‬
‪‪2.00 B‬‬
‪‪3.00 B‬‬
‪‪4.00 B‬‬
Assets
Liabilities